Drug
Inclacumab clinical trials
Also written RO4905417.
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses inclacumab is read from its arms, and is right about nine times in ten.
Testing it · 7
- A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell DiseaseTerminatedPhase 3PfizerNCT05348915Written as Inclacumab
- A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive CrisesCompletedPhase 3PfizerNCT04935879Written as Inclacumab
- A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive CrisesTerminatedPhase 3PfizerNCT04927247Written as Inclacumab
- A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01815827Written as inclacumab
- A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).CompletedPhase 1Hoffmann-La RocheNCT00760565Written as RO4905417
- A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) SurgeryCompletedPhase 2Hoffmann-La RocheNCT01245634Written as RO4905417
- A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary InterventionCompletedPhase 2Hoffmann-La RocheNCT01327183Written as RO4905417
Codes
What other systems call inclacumab · ClinicalTrials.gg INT000388
- MeSH (NLM) C000604431inclacumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) A6734I702LINCLACUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q13218585InclacumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174603InclacumabOne source FDA
- DrugBank DB12246One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604431 | inclacumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | A6734I702L | INCLACUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q13218585 | Inclacumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174603 | Inclacumab | One source FDA |
| DrugBank | DB12246 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.